Fig. 6: T3 cells preserve healthy hematopoiesis in vivo.
From: T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
a,b, FACS analysis of viable human CD19−HLA-DRneg thymocytes (a), and spaghetti-plot illustrating HLA-A2 and TdT mean fluorescence intensity (MFI) at distinct stages of T-cell development (b), defined as shown in Extended Data Fig. 9a, in human thymus. c, Experimental overview of humanized NSG (hu-NSG) mouse model used to investigate the effect of T3-cell therapy on healthy human hematopoiesis. d, Percentage of human TdTpos cells in thymus of hu-NSG mice (n = 8 per group). e, HLA-A2 mean fluorescence intensity of TdTpos cells (hCD45+ TdTpos) and surface CD3+ (s-CD3+) human thymocytes derived from one normal human thymus and from thymus of 1G4 (n = 8) and T3 (n = 8)-treated humanized mice. f, Percentage of TCR-transduced CD8+ cells in PB at indicated days after T-cell infusion (n = 8 per group). g, Myeloid and erythroid colonies generated from sorted normal adult human BM CD34+ cells (n = 4 biological replicates, data pooled from two independent experiments) following coculture with or without 1G4, T1 or T3 cells for 72 h at an E/T ratio of 2/1. All data are presented as mean ± s.e.m.; dots in d–f represent individual mice at terminal analysis on day 17 post treatment, unless otherwise stated.
